Summit Therapeutics (SMMT) Debt to Equity (2018 - 2024)
Historic Debt to Equity for Summit Therapeutics (SMMT) over the last 6 years, with Q1 2024 value amounting to $2.26.
- Summit Therapeutics' Debt to Equity rose 20192.72% to $2.26 in Q1 2024 from the same period last year, while for Mar 2024 it was $2.26, marking a year-over-year increase of 20192.72%. This contributed to the annual value of $1.29 for FY2023, which is 6703.59% down from last year.
- Per Summit Therapeutics' latest filing, its Debt to Equity stood at $2.26 for Q1 2024, which was up 20192.72% from $1.29 recorded in Q4 2023.
- Summit Therapeutics' Debt to Equity's 5-year high stood at $3.9 during Q4 2022, with a 5-year trough of -$0.0 in Q1 2020.
- In the last 4 years, Summit Therapeutics' Debt to Equity had a median value of $0.79 in 2023 and averaged $1.24.
- As far as peak fluctuations go, Summit Therapeutics' Debt to Equity crashed by 6703.59% in 2023, and later soared by 20192.72% in 2024.
- Over the past 4 years, Summit Therapeutics' Debt to Equity (Quarter) stood at -$0.0 in 2020, then surged by 266285.12% to $3.9 in 2022, then crashed by 67.04% to $1.29 in 2023, then surged by 75.73% to $2.26 in 2024.
- Its last three reported values are $2.26 in Q1 2024, $1.29 for Q4 2023, and $0.84 during Q2 2023.